Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi

Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for Mytesi ® ...

Article About Groundbreaking Results from Study of Jaguar Health’s Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publicati…

Crofelemer has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) and the European Medicines ...

Jaguar Health, Inc.: Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi

Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for Mytesi and Canalevia-CA1, which has the potential to provide Jaguar up to an additi ...

Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million

Future Pak becomes exclusive U.S. marketer for Mytesi® and Canalevia®-CA1 Meaningful non-dilutive capital enables Jaguar to ...
TipRanks on MSN

Jaguar Health announces article featuring crofelemer study results

Jaguar Health (JAGX) announced that an article published December 29, 2025 in HEALTH, a bi-monthly English and Arabic healthcare magazine in the ...

Jaguar Health, Inc.: Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates ...

Article discusses results demonstrating parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failureAssociated ...